Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Checkpoint Therapeutics in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.94) per share for the year, down from their prior forecast of ($0.80). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Checkpoint Therapeutics' current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Checkpoint Therapeutics' Q4 2024 earnings at ($0.22) EPS.
Checkpoint Therapeutics Price Performance
Shares of CKPT stock traded down $0.13 during trading hours on Monday, reaching $3.30. 779,675 shares of the company were exchanged, compared to its average volume of 525,010. The stock's fifty day moving average is $2.84 and its two-hundred day moving average is $2.37. Checkpoint Therapeutics has a fifty-two week low of $1.36 and a fifty-two week high of $3.97. The company has a market cap of $148.56 million, a price-to-earnings ratio of -1.79 and a beta of 1.23.
Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08).
Hedge Funds Weigh In On Checkpoint Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of CKPT. XTX Topco Ltd purchased a new stake in shares of Checkpoint Therapeutics during the second quarter worth $34,000. Gladstone Institutional Advisory LLC increased its stake in Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company's stock valued at $78,000 after buying an additional 20,500 shares during the period. Magnus Financial Group LLC raised its stake in shares of Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company's stock valued at $78,000 after buying an additional 4,000 shares in the last quarter. 180 Wealth Advisors LLC bought a new position in Checkpoint Therapeutics during the 2nd quarter worth approximately $96,000. Finally, Choreo LLC increased its holdings in Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company's stock worth $133,000 after buying an additional 7,080 shares during the last quarter. Institutional investors own 22.00% of the company's stock.
About Checkpoint Therapeutics
(
Get Free Report)
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
Before you consider Checkpoint Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.
While Checkpoint Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
